Project Grant HT94252310985
Award Date
9/30/23
Completion Date
9/29/25
Dollars Obligated
$680K
Federal Agency
Defense Health Agency
Awardee
Dignity Health (SKX6AXF9ZTM3)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
The Department of the Army Medical Command awarded a $722,545 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Dignity Health's St. Joseph's Hospital and Medical Center in San Francisco, CA. The grant will fund a 2-year research project to investigate the role of TDP-43 associated cryptic exon inclusion in C9ORF72-mediated cortical neurodegeneration. The project aims to advance understanding of the molecular mechanisms underlying neurological disorders...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,078,882 to the Sanford Burnham Prebys Medical Discovery Institute to conduct advanced chemical engineering research on amyotrophic lateral sclerosis (ALS). The research aims to take a more sophisticated, multimodal approach to understanding the therapeutic actions of donor and host neural stem cells in ALS. The award includes a sub-grant to the J. David...
This $993,283 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of California, San Francisco (UCSF) aimed at transforming healthcare for military service members, veterans, and the broader public. The 2-year award, effective from September 1, 2025 to August 31, 2027, will fund proteomic research to investigate determinants and components of disease progression in multiple...
The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
This federal Project Grant award, issued by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $963,000.00 to The Regents of the University of California, doing business as University of California, Berkeley, to conduct research on "REBALANCING C9ORF72 LOSS OF FUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS". The research, which will take place over a two-year period from March 1, 2024 to February 28, 2026, aims to...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
This federal Project Grant award of $999,999.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research into cell-free DNA epigenetic biomarkers for multiple sclerosis. The award was granted on August 1, 2025 to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution. The project aims to transform healthcare for military service...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports the development and evaluation of a care pathway for the respiratory syndromes of amyotrophic lateral sclerosis (ALS). The $2,311,734 award to the Denver Research Institute, a non-profit research organization, will fund this 4-year project from July 1, 2025 to June 30, 2029. The goal is to create and assess a comprehensive care pathway to improve the...